Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 502

1.

Safety of Abatacept Versus Placebo in Rheumatoid Arthritis: Integrated Data Analysis of Nine Clinical Trials.

Simon TA, Soule BP, Hochberg M, Fleming D, Torbeyns A, Banerjee S, Boers M.

ACR Open Rheumatol. 2019 May 29;1(4):251-257. doi: 10.1002/acr2.1034. eCollection 2019 Jun.

2.

Use of composite outcomes facilitate core outcome set uptake in rheumatoid arthritis trials.

Kirkham J, Christensen R, Boers M.

Ann Rheum Dis. 2019 Nov 19. pii: annrheumdis-2019-216256. doi: 10.1136/annrheumdis-2019-216256. [Epub ahead of print] No abstract available.

PMID:
31744828
3.

Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study.

Simon TA, Boers M, Hochberg M, Baker N, Skovron ML, Ray N, Singhal S, Suissa S, Gomez-Caminero A.

Arthritis Res Ther. 2019 Nov 8;21(1):228. doi: 10.1186/s13075-019-1992-x.

4.

PROMIS Physical Function Short Forms Display Item- and Scale-Level Characteristics at Least as Good as the Roland Morris Disability Questionnaire in Patients With Chronic Low Back Pain.

Chiarotto A, Roorda LD, Crins MH, Boers M, Ostelo RW, Terwee CB.

Arch Phys Med Rehabil. 2019 Nov 2. pii: S0003-9993(19)31362-0. doi: 10.1016/j.apmr.2019.09.018. [Epub ahead of print]

PMID:
31689418
5.

Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty.

Boers M.

Ann Intern Med. 2019 Nov 5;171(9):679-680. doi: 10.7326/L19-0527. No abstract available.

PMID:
31683279
6.

Older Drugs With Limited Trial Evidence: Are They Worth the Expense?

Boers M.

Ann Intern Med. 2019 Oct 15;171(8):601. doi: 10.7326/L19-0518. No abstract available.

PMID:
31610563
7.

First Validation of the Full PROMIS Pain Interference and Pain Behavior Item Banks in Patients with Rheumatoid Arthritis.

Crins MHP, Terwee CB, Westhovens R, van Schaardenburg D, Smits N, Joly J, Verschueren P, Van der Elst K, Dekker J, Boers M, Roorda LD.

Arthritis Care Res (Hoboken). 2019 Sep 28. doi: 10.1002/acr.24077. [Epub ahead of print]

PMID:
31562795
8.

Influence of Infant Cleft Dimensions on Velopharyngeal Function in 5-Year-Old Danish Children Born With Unilateral Cleft Lip and Palate.

Botticelli S, Küseler A, Mølsted K, Andersen HS, Boers M, Shoeps A, Emborg BK, Kisling-Møller M, Pedersen TK, Andersen M, Willadsen E.

Cleft Palate Craniofac J. 2019 Sep 10:1055665619874143. doi: 10.1177/1055665619874143. [Epub ahead of print]

PMID:
31505955
9.

Zoledronate in the prevention of Paget's (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget's disease of bone.

Cronin O, Forsyth L, Goodman K, Lewis SC, Keerie C, Walker A, Porteous M, Cetnarskyj R, Ranganath LR, Selby PL, Hampson G, Chandra R, Ho S, Tobias JH, Young-Min S, McKenna MJ, Crowley RK, Fraser WD, Gennari L, Nuti R, Brandi ML, Del Pino-Montes J, Devogelaer JP, Durnez A, Isaia G, Di Stefano M, Guañabens N, Blanch J, Seibel MJ, Walsh JP, Kotowicz MA, Nicholson GC, Duncan EL, Major G, Horne A, Gilchrist NL, Boers M, Murray GD, Charnock K, Wilkinson D, Russell RGG, Ralston SH.

BMJ Open. 2019 Sep 4;9(9):e030689. doi: 10.1136/bmjopen-2019-030689.

10.

No association between participant retention and the proportion of included elderly people in rheumatology trials: Results from a series of exploratory meta-regression analyses.

Palmowski A, Nielsen SM, Buttgereit T, Palmowski Y, Boers M, Christensen R, Buttgereit F.

Arthritis Care Res (Hoboken). 2019 Aug 17. doi: 10.1002/acr.24051. [Epub ahead of print]

PMID:
31421022
11.

Mortality has improved in RA, but we must remain vigilant. Response to: 'Early intensive treatment normalises excess mortality in ACPA-negative RA but not in ACPA-positive RA' by Matthijssen et al.

Poppelaars PBM, van Tuyl LHD, Boers M.

Ann Rheum Dis. 2019 Jul 8. pii: annrheumdis-2019-215863. doi: 10.1136/annrheumdis-2019-215863. [Epub ahead of print] No abstract available.

PMID:
31285259
12.

Glucocorticoids for rheumatoid arthritis in the era of targeted therapies.

Boers M.

Reumatol Clin. 2019 Nov - Dec;15(6):311-314. doi: 10.1016/j.reuma.2019.05.003. Epub 2019 Jun 22. English, Spanish. No abstract available.

13.

Suboptimal cardiovascular risk management in rheumatoid arthritis patients despite an explicit cardiovascular risk screening programme.

Heslinga M, Van Den Oever I, Jonker DL, Griep EN, Griep-Wentink H, Smulders YM, Lems WF, Boers M, Voskuyl AE, Peters M, Van Schaardenburg D, Nurmohamed MT.

Scand J Rheumatol. 2019 Sep;48(5):345-352. doi: 10.1080/03009742.2019.1600718. Epub 2019 Jun 18.

PMID:
31210083
14.

Scandcleft Project, Trial 1: Comparison of Speech Outcome in Relation to Timing of Hard Palate Closure in 5-Year-Olds With UCLP.

Willadsen E, Lohmander A, Persson C, Boers M, Kisling-Møller M, Havstam C, Elander A, Andersen M.

Cleft Palate Craniofac J. 2019 Nov;56(10):1276-1286. doi: 10.1177/1055665619854632. Epub 2019 Jun 12.

PMID:
31189334
15.

Predictors of sick leave and improved worker productivity after 52 weeks of intensive treatment in patients with early rheumatoid arthritis.

Blomjous BS, Boers M, Den Uyl D, Twisk J, Van Schaardenburg D, Voskuyl AE, Lems WF, Ter Wee MM.

Scand J Rheumatol. 2019 Jul;48(4):271-278. doi: 10.1080/03009742.2019.1570549. Epub 2019 May 28.

PMID:
31135239
16.

Remarkable international variability in reasons for ineligibility and non-participation in the GLORIA trial.

Hartman L, Bos R, Buttgereit F, Güler-Yuksel M, Ionescu R, Kok MR, Lems WF, Micaelo M, Opris-Belinski D, Pusztai A, Santos E, Da Silva J, Szekanecz Z, Zeiner K, Zhang D, Boers M.

Scand J Rheumatol. 2019 Jul;48(4):340-341. doi: 10.1080/03009742.2018.1559880. Epub 2019 May 27. No abstract available.

PMID:
31132016
17.

Cardiovascular Event Risk in Rheumatoid Arthritis Compared with Type 2 Diabetes: A 15-year Longitudinal Study.

Agca R, Hopman LHGA, Laan KJC, van Halm VP, Peters MJL, Smulders YM, Dekker JM, Nijpels G, Stehouwer CDA, Voskuyl AE, Boers M, Lems WF, Nurmohamed MT.

J Rheumatol. 2019 May 15. pii: jrheum.180726. doi: 10.3899/jrheum.180726. [Epub ahead of print]

PMID:
31092721
18.

Response to: 'Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS study' by Marotte et al.

l'Ami MJ, Krieckaert CL, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, Wolbink GJ.

Ann Rheum Dis. 2019 May 9. pii: annrheumdis-2019-215609. doi: 10.1136/annrheumdis-2019-215609. [Epub ahead of print] No abstract available.

PMID:
31072816
19.

An updated review of glucocorticoid-related adverse events in patients with rheumatoid arthritis.

Luís M, Freitas J, Costa F, Buttgereit F, Boers M, Jap DS, Santiago T.

Expert Opin Drug Saf. 2019 Jul;18(7):581-590. doi: 10.1080/14740338.2019.1615052. Epub 2019 May 14. Review.

PMID:
31056959
20.

Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials.

Klokker L, Berthelsen DB, Woodworth T, Andersen KM, Furst DE, Devoe D, Williamson PR, Suarez-Almazor ME, Strand V, Leong AL, Goel N, Boers M, Brooks PM, March L, Sloan VS, Tugwell P, Simon LS, Christensen R.

J Rheumatol. 2019 Sep;46(9):1173-1178. doi: 10.3899/jrheum.190196. Epub 2019 May 1.

PMID:
31043547
21.

Systematic review of rheumatoid arthritis clinical studies: Suboptimal statistical analysis of radiological data.

Mahmood S, van Tuyl L, Schoonmade LJ, Landewé R, van der Heijde D, Twisk J, Boers M.

Semin Arthritis Rheum. 2019 Oct;49(2):218-221. doi: 10.1016/j.semarthrit.2019.02.009. Epub 2019 Feb 21. Review.

PMID:
30878153
22.

The OMERACT Stepwise Approach to Select and Develop Imaging Outcome Measurement Instruments: The Musculoskeletal Ultrasound Example.

Terslev L, Naredo E, Keen HI, Bruyn GAW, Iagnocco A, Wakefield RJ, Conaghan PG, Maxwell LJ, Beaton DE, Boers M, D'Agostino MA.

J Rheumatol. 2019 Oct;46(10):1394-1400. doi: 10.3899/jrheum.181158. Epub 2019 Mar 15.

PMID:
30877208
23.

Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017.

Smith TO, Mansfield M, Hawker GA, Hunter DJ, March LM, Boers M, Shea BJ, Christensen R, Guillemin F, Terwee CB, Williamson PR, Roos EM, Loeser RF, Schnitzer TJ, Kloppenburg M, Neogi T, Ladel CH, Kalsi G, Kaiser U, Buttel TW, Ashford AE, Mobasheri A, Arden NK, Tennant A, Hochberg MC, de Wit M, Tugwell P, Conaghan PG.

J Rheumatol. 2019 Aug;46(8):976-980. doi: 10.3899/jrheum.181066. Epub 2019 Mar 1.

PMID:
30824657
24.

Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up.

Poppelaars PBM, van Tuyl LHD, Boers M.

Ann Rheum Dis. 2019 May;78(5):586-589. doi: 10.1136/annrheumdis-2018-214618. Epub 2019 Feb 26.

PMID:
30808623
25.

OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies.

Boers M, Beaton DE, Shea BJ, Maxwell LJ, Bartlett SJ, Bingham CO 3rd, Conaghan PG, D'Agostino MA, de Wit MP, Gossec L, March L, Simon LS, Singh JA, Strand V, Wells GA, Tugwell P.

J Rheumatol. 2019 Aug;46(8):1021-1027. doi: 10.3899/jrheum.181096. Epub 2019 Feb 15.

PMID:
30770515
26.

Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group.

Pickles T, Alten R, Boers M, Bykerk V, Christensen J, Christensen R, van Hoogstraten H, Simon LS, Tam LS, Choy EH.

J Rheumatol. 2019 Oct;46(10):1406-1408. doi: 10.3899/jrheum.181054. Epub 2019 Feb 15.

PMID:
30770514
27.

Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology.

Maxwell LJ, Beaton DE, Shea BJ, Wells GA, Boers M, Grosskleg S, Bingham CO 3rd, Conaghan PG, D'Agostino MA, de Wit M, Gossec L, March L, Simon LS, Singh JA, Strand V, Tugwell P.

J Rheumatol. 2019 Aug;46(8):1014-1020. doi: 10.3899/jrheum.181097. Epub 2019 Feb 15.

PMID:
30770502
28.

Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology.

Beaton DE, Maxwell LJ, Shea BJ, Wells GA, Boers M, Grosskleg S, Bingham CO 3rd, Conaghan PG, D'Agostino MA, de Wit MP, Gossec L, March LM, Simon LS, Singh JA, Strand V, Tugwell P.

J Rheumatol. 2019 Aug;46(8):1028-1035. doi: 10.3899/jrheum.181218. Epub 2019 Feb 1.

PMID:
30709952
29.

Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay.

Berkhout LC, l'Ami MJ, Ruwaard J, Hart MH, Heer PO, Bloem K, Nurmohamed MT, van Vollenhoven RF, Boers M, Alvarez DF, Smith CH, Wolbink GJ, Rispens T.

Sci Transl Med. 2019 Jan 30;11(477). pii: eaat3356. doi: 10.1126/scitranslmed.aat3356.

PMID:
30700574
30.

The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee Osteoarthritis.

Smith TO, Hawker GA, Hunter DJ, March LM, Boers M, Shea BJ, Christensen R, Guillemin F, Terwee CB, Williamson PR, Dodd S, Roos EM, Loeser RF, Schnitzer TJ, Kloppenburg M, Neogi T, Ladel CH, Kalsi G, Kaiser U, Buttel TW, Ashford AE, Mobasheri A, Arden NK, Tennant A, Hochberg MC, de Wit M, Tugwell P, Conaghan PG.

J Rheumatol. 2019 Aug;46(8):981-989. doi: 10.3899/jrheum.181194. Epub 2019 Jan 15.

PMID:
30647185
31.

Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative.

Nielsen SM, Tugwell P, de Wit MPT, Boers M, Beaton DE, Woodworth TG, Escorpizo R, Shea B, Toupin-April K, Guillemin F, Strand V, Singh JA, Kloppenburg M, Furst DE, Wells GA, Smolen JS, Veselý R, Boonen A, Storgaard H, Voshaar M, March L, Christensen R; Contextual Factors Working Group.

J Rheumatol. 2019 Sep;46(9):1159-1163. doi: 10.3899/jrheum.181081. Epub 2019 Jan 15.

PMID:
30647174
32.

Applicability of trials in rheumatoid arthritis and osteoarthritis: A systematic review and meta-analysis of trial populations showing adequate proportion of women, but underrepresentation of elderly people.

Palmowski A, Buttgereit T, Palmowski Y, Nielsen SM, Boers M, Christensen R, Buttgereit F.

Semin Arthritis Rheum. 2019 Jun;48(6):983-989. doi: 10.1016/j.semarthrit.2018.10.017. Epub 2018 Nov 2.

PMID:
30466715
33.

Effects of Co-medication with Glucocorticoids in Biologics Trials.

Boers M.

J Rheumatol. 2018 Nov;45(11):1605. doi: 10.3899/jrheum.180151. Epub 2018 Nov 1. No abstract available.

PMID:
30385699
34.

Validation of two PROMIS item banks for measuring social participation in the Dutch general population.

Terwee CB, Crins MHP, Boers M, de Vet HCW, Roorda LD.

Qual Life Res. 2019 Jan;28(1):211-220. doi: 10.1007/s11136-018-1995-0. Epub 2018 Sep 10.

35.

Outcome measures for adherence data from a medication event monitoring system: A literature review.

Hartman L, Lems WF, Boers M.

J Clin Pharm Ther. 2019 Feb;44(1):1-5. doi: 10.1111/jcpt.12757. Epub 2018 Sep 1. Review.

PMID:
30171815
36.

Measurement Properties of Visual Analogue Scale, Numeric Rating Scale, and Pain Severity Subscale of the Brief Pain Inventory in Patients With Low Back Pain: A Systematic Review.

Chiarotto A, Maxwell LJ, Ostelo RW, Boers M, Tugwell P, Terwee CB.

J Pain. 2019 Mar;20(3):245-263. doi: 10.1016/j.jpain.2018.07.009. Epub 2018 Aug 10. Review.

PMID:
30099210
37.

Excessive Pricing Causes Poor Access to Biologics.

Boers M.

J Rheumatol. 2018 Jun;45(6):876. doi: 10.3899/jrheum.171401. No abstract available.

PMID:
29858458
38.

Evidence on the measurement properties of health-related quality of life instruments is largely missing in patients with low back pain: A systematic review.

Chiarotto A, Terwee CB, Kamper SJ, Boers M, Ostelo RW.

J Clin Epidemiol. 2018 Oct;102:23-37. doi: 10.1016/j.jclinepi.2018.05.006. Epub 2018 May 21. Review.

PMID:
29793009
39.

Evaluation of the wear-and-tear scale for therapeutic footwear, results of a generalizability study.

Dahmen R, Siemonsma PC, Monteiro S, Norman GR, Boers M, Lankhorst GJ, Roorda LD.

J Rehabil Med. 2018 Jun 15;50(6):569-574. doi: 10.2340/16501977-2339.

40.

Designing effective graphs to get your message across.

Boers M.

Ann Rheum Dis. 2018 Jun;77(6):833-839. doi: 10.1136/annrheumdis-2018-213396. Review. Erratum in: Ann Rheum Dis. 2019 Mar;78(3):442.

PMID:
29748338
41.

A Novel Method to Combine Assessment of Benefit and Harm: Outcome Measures in Rheumatology 3×3 Methodology Applied to Two Active Comparator Trials.

Boers M, Singh JA, Cofield SS, Bridges SL Jr, Moreland LW, O'Dell JR, Wu H, Leatherman S, Curtis JR.

Arthritis Care Res (Hoboken). 2019 Feb;71(2):319-322. doi: 10.1002/acr.23590. Epub 2019 Jan 10.

PMID:
29691998
42.

Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative).

Chalmers JR, Thomas KS, Apfelbacher C, Williams HC, Prinsen CA, Spuls PI, Simpson E, Gerbens LAA, Boers M, Barbarot S, Stalder JF, Abuabara K, Aoki V, Ardeleanu M, Armstrong J, Bang B, Berents TL, Burton T, Butler L, Chubachi T, Cresswell-Melville A, DeLozier A, Eckert L, Eichenfield L, Flohr C, Futamura M, Gadkari A, Gjerde ES, van Halewijn KF, Hawkes C, Howells L, Howie L, Humphreys R, Ishii HA, Kataoka Y, Katayama I, Kouwenhoven W, Langan SM, Leshem YA, Merhand S, Mina-Osorio P, Murota H, Nakahara T, Nunes FP, Nygaard U, Nygårdas M, Ohya Y, Ono E, Rehbinder E, Rogers NK, Romeijn GLE, Schuttelaar MLA, Sears AV, Simpson MA, Singh JA, Srour J, Stuart B, Svensson Å, Talmo G, Talmo H, Teixeira HD, Thyssen JP, Todd G, Torchet F, Volke A, von Kobyletzki L, Weisshaar E, Wollenberg A, Zaniboni M.

Br J Dermatol. 2018 May;178(5):e332-e341. doi: 10.1111/bjd.16543. Epub 2018 Apr 19.

PMID:
29672835
43.

An unfavorable body composition is common in early arthritis patients: A case control study.

Turk SA, van Schaardenburg D, Boers M, de Boer S, Fokker C, Lems WF, Nurmohamed MT.

PLoS One. 2018 Mar 22;13(3):e0193377. doi: 10.1371/journal.pone.0193377. eCollection 2018.

44.

The controversy of using PGA to define remission in RA.

van Tuyl LHD, Boers M.

Nat Rev Rheumatol. 2018 Mar 21;14(4):245. doi: 10.1038/nrrheum.2018.36. No abstract available.

PMID:
29559715
45.

Prevalence and validity of ACR/EULAR remission in four European early rheumatoid arthritis cohorts.

Britsemmer K, van Schaardenburg D, Boers M, De Cock D, Verschueren P, Radner H, Smolen JS, van Tuyl LHD.

Clin Exp Rheumatol. 2018 May-Jun;36(3):362-370. Epub 2018 Feb 26.

PMID:
29533752
46.

Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial.

Hartman L, Rasch LA, Klausch T, Bijlsma HWJ, Christensen R, Smulders YM, Ralston SH, Buttgereit F, Cutolo M, Da Silva JAP, Opris D, Rovenský J, Szamosi S, Middelink LM, Lems WF, Boers M.

Trials. 2018 Jan 25;19(1):67. doi: 10.1186/s13063-017-2396-3.

47.

Core outcome measurement instruments for clinical trials in nonspecific low back pain.

Chiarotto A, Boers M, Deyo RA, Buchbinder R, Corbin TP, Costa LOP, Foster NE, Grotle M, Koes BW, Kovacs FM, Lin CC, Maher CG, Pearson AM, Peul WC, Schoene ML, Turk DC, van Tulder MW, Terwee CB, Ostelo RW.

Pain. 2018 Mar;159(3):481-495. doi: 10.1097/j.pain.0000000000001117.

48.

A systematic review highlights the need to investigate the content validity of patient-reported outcome measures for physical functioning in patients with low back pain.

Chiarotto A, Ostelo RW, Boers M, Terwee CB.

J Clin Epidemiol. 2018 Mar;95:73-93. doi: 10.1016/j.jclinepi.2017.11.005. Epub 2017 Nov 14. Review.

PMID:
29154811
49.

More erroneous statements about the use of frequentist statistical methods in medical research.

Boers M.

Clin Exp Rheumatol. 2019 Nov-Dec;37 Suppl 122(6):4. Epub 2017 Oct 26. No abstract available.

50.

Response to: Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' by den Broeder et al.

l'Ami MJ, Krieckaert CLM, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, Wolbink GJ.

Ann Rheum Dis. 2018 Oct;77(10):e68. doi: 10.1136/annrheumdis-2017-212602. Epub 2017 Nov 13. No abstract available.

PMID:
29133475

Supplemental Content

Support Center